FDA's Shift Away from Expert Reviews Sparks Industry Concerns
TL;DR Summary
Under the Trump administration, the FDA is moving to phase out the practice of consulting outside experts for drug reviews, citing efficiency, but critics argue this reduces transparency and public oversight, potentially impacting the rigor and accountability of drug approval processes.
- Under Trump, FDA seeks to abandon expert reviews of new drugs CNN
- Top drug regulator pushes back on report that FDA wants to ‘abandon’ some adcomms Endpoints News
- FDA panels, politics and power: the shifting balance The Pharma Letter
- Pharmalittle: We're reading about FDA adcomms, Kenvue lobbying RFK Jr. about Tylenol, and more statnews.com
- FDA Abandoning Expert Reviews: Implications for Drug Developers and Quality Professionals PharmTech
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
7 min
vs 8 min read
Condensed
97%
1,404 → 41 words
Want the full story? Read the original article
Read on CNN